{
  "symbol": "UNH",
  "year": 2023,
  "Period": "Q2",
  "report_type": "Q10",
  "metrics": {
    "mdna_sentiment": 0.0,
    "outlook_sentiment": 0.1785,
    "forward_ratio": 1.0,
    "hedge_ratio": 0.192
  },
  "top_positive": [
    {
      "sent": "FINANCIAL STATEMENTS UnitedHealth Group Condensed Consolidated Balance Sheets (Unaudited) (in millions, except per share data) June 30, 2023 December 31, 2022 Assets Current assets: Cash and cash equivalents $ 41,813 $ 23,365 Short-term investments 4,466 4,546 Accounts receivable, net 17,952 17,681 Other current receivables, net 16,131 12,769 Assets under management 3,623 4,087 Prepaid expenses and other current assets 5,884 6,621 Total current assets 89,869 69,069 Long-term investments 45,988 43,728 Property, equipment and capitalized software, net 10,926 10,128 Goodwill 101,669 93,352 Other intangible assets, net 15,643 14,401 Other assets 16,069 15,027 Total assets $ 280,164 $ 245,705 Liabilities, redeemable noncontrolling interests and equity Current liabilities: Medical costs payable $ 31,947 $ 29,056 Accounts payable and accrued liabilities 29,516 27,715 Short-term borrowings and current maturities of long-term debt 6,321 3,110 Unearned revenues 14,852 3,075 Other current liabilities 30,345 26,281 Total current liabilities 112,981 89,237 Long-term debt, less current maturities 59,268 54,513 Deferred income taxes 2,498 2,769 Other liabilities 13,261 12,839 Total liabilities 188,008 159,358 Commitments and contingencies (Note 7) Redeemable noncontrolling interests 4,788 4,897 Equity: Preferred stock, $ 0.001 par value - 10 shares authorized; no shares issued or outstanding \u2014 \u2014 Common stock, $ 0.01 par value - 3,000 shares authorized; 927 and 934 issued and outstanding 9 9 Retained earnings 89,994 86,156 Accumulated other comprehensive loss ( 7,650 ) ( 8,393 ) Nonredeemable noncontrolling interests 5,015 3,678 Total equity 87,368 81,450 Total liabilities, redeemable noncontrolling interests and equity $ 280,164 $ 245,705 See Notes to the Condensed Consolidated Financial Statements 1 Table of Contents UnitedHealth Group Condensed Consolidated Statements of Operations (Unaudited) Three Months Ended June 30, Six Months Ended June 30, (in millions, except per share data) 2023 2022 2023 2022 Revenues: Premiums $ 72,474 $ 63,896 $ 145,260 $ 127,966 Products 10,651 9,496 20,918 18,836 Services 8,663 6,645 16,743 13,017 Investment and other income 1,115 295 1,913 662 Total revenues 92,903 80,332 184,834 160,481 Operating costs: Medical costs 60,268 52,093 120,113 104,616 Operating costs 13,809 11,709 27,434 23,110 Cost of products sold 9,748 8,596 19,153 17,083 Depreciation and amortization 1,021 802 1,991 1,590 Total operating costs 84,846 73,200 168,691 146,399 Earnings from operations 8,057 7,132 16,143 14,082 Interest expense ( 828 ) ( 467 ) ( 1,582 ) ( 900 ) Earnings before income taxes 7,229 6,665 14,561 13,182 Provision for income taxes ( 1,572 ) ( 1,466 ) ( 3,130 ) ( 2,835 ) Net earnings 5,657 5,199 11,431 10,347 Earnings attributable to noncontrolling interests ( 183 ) ( 129 ) ( 346 ) ( 250 ) Net earnings attributable to UnitedHealth Group common shareholders $ 5,474 $ 5,070 11,085 $ 10,097 Earnings per share attributable to UnitedHealth Group common shareholders: Basic $ 5.89 $ 5.41 $ 11.91 $ 10.75 Diluted $ 5.82 $ 5.34 $ 11.77 $ 10.61 Basic weighted-average number of common shares outstanding 930 937 931 939 Dilutive effect of common share equivalents 10 13 11 13 Diluted weighted-average number of common shares outstanding 940 950 942 952 Anti-dilutive shares excluded from the calculation of dilutive effect of common share equivalents 7 3 6 3 See Notes to the Condensed Consolidated Financial Statements 2 Table of Contents UnitedHealth Group Condensed Consolidated Statements of Comprehensive Income (Unaudited) Three Months Ended June 30, Six Months Ended June 30, (in millions) 2023 2022 2023 2022 Net earnings $ 5,657 $ 5,199 $ 11,431 $ 10,347 Other comprehensive (loss) income: Gross unrealized (losses) gains on investment securities during the period ( 431 ) ( 1,331 ) 209 ( 3,354 ) Income tax effect 99 304 ( 48 ) 769 Total unrealized (losses) gains, net of tax ( 332 ) ( 1,027 ) 161 ( 2,585 ) Gross reclassification adjustment for net realized gains included in net earnings ( 47 ) ( 1 ) ( 34 ) ( 4 ) Income tax effect 11 \u2014 8 1 Total reclassification adjustment, net of tax ( 36 ) ( 1 ) ( 26 ) ( 3 ) Total foreign currency translation gains (losses) 267 ( 676 ) 608 242 Other comprehensive (loss) income ( 101 ) ( 1,704 ) 743 ( 2,346 ) Comprehensive income 5,556 3,495 12,174 8,001 Comprehensive income attributable to noncontrolling interests ( 183 ) ( 129 ) ( 346 ) ( 250 ) Comprehensive income attributable to UnitedHealth Group common shareholders $ 5,373 $ 3,366 $ 11,828 $ 7,751 See Notes to the Condensed Consolidated Financial Statements 3 Table of Contents UnitedHealth Group Condensed Consolidated Statements of Changes in Equity (Unaudited) Common Stock Additional Paid-In Capital Retained Earnings Accumulated Other Comprehensive (Loss) Income Nonredeemable Noncontrolling Interests Total Equity Three months ended June 30, (in millions) Shares Amount Net Unrealized (Losses) Gains on Investments Foreign Currency Translation (Losses) Gains Balance at March 31, 2023 932 $ 9 $ \u2014 $ 88,852 $ ( 2,275 ) $ ( 5,274 ) $ 4,509 $ 85,821 Net earnings 5,474 139 5,613 Other comprehensive (loss) income ( 368 ) 267 ( 101 ) Issuances of common stock, and related tax effects 1 \u2014 218 218 Share-based compensation 232 232 Common share repurchases ( 6 ) \u2014 ( 442 ) ( 2,585 ) ( 3,027 ) Cash dividends paid on common shares ($ 1.88 per share) ( 1,747 ) ( 1,747 ) Redeemable noncontrolling interests fair value and other adjustments ( 8 ) ( 8 ) Acquisition and other adjustments of nonredeemable noncontrolling interests 478 478 Distribution to nonredeemable noncontrolling interests ( 111 ) ( 111 ) Balance at June 30, 2023 927 $ 9 $ \u2014 $ 89,994 $ ( 2,643 ) $ ( 5,007 ) $ 5,015 $ 87,368 Balance at March 31, 2022 939 $ 10 $ \u2014 $ 78,782 $ ( 1,137 ) $ ( 4,889 ) $ 3,362 $ 76,128 Net earnings 5,070 94 5,164 Other comprehensive loss ( 1,028 ) ( 676 ) ( 1,704 ) Issuances of common stock, and related tax effects 1 \u2014 174 174 Share-based compensation 194 194 Common share repurchases ( 5 ) \u2014 ( 733 ) ( 1,767 ) ( 2,500 ) Cash dividends paid on common shares ($ 1.65 per share) ( 1,545 ) ( 1,545 ) Redeemable noncontrolling interests fair value and other adjustments 365 365 Acquisition and other adjustments of nonredeemable noncontrolling interests 12 12 Distribution to nonredeemable noncontrolling interests ( 83 ) ( 83 ) Balance at June 30, 2022 935 $ 10 $ \u2014 $ 80,540 $ ( 2,165 ) $ ( 5,565 ) $ 3,385 $ 76,205 See Notes to the Condensed Consolidated Financial Statements 4 Table of Contents UnitedHealth Group Condensed Consolidated Statements of Changes in Equity (Unaudited) Common Stock Additional Paid-In Capital Retained Earnings Accumulated Other Comprehensive (Loss) Income Nonredeemable Noncontrolling Interests Total Equity Six months ended March 31, (in millions) Shares Amount Net Unrealized (Losses) Gains on Investments Foreign Currency Translation (Losses) Gains Balance at January 1, 2023 934 $ 9 $ \u2014 $ 86,156 $ ( 2,778 ) $ ( 5,615 ) $ 3,678 $ 81,450 Net earnings 11,085 252 11,337 Other comprehensive income 135 608 743 Issuances of common stock, and related tax effects 3 \u2014 568 568 Share-based compensation 598 598 Common share repurchases ( 10 ) \u2014 ( 1,075 ) ( 3,963 ) ( 5,038 ) Cash dividends paid on common shares ($ 3.53 per share) ( 3,284 ) ( 3,284 ) Redeemable noncontrolling interests fair value and other adjustments ( 91 ) ( 91 ) Acquisition and other adjustments of nonredeemable noncontrolling interests 1,297 1,297 Distribution to nonredeemable noncontrolling interests ( 212 ) ( 212 ) Balance at June 30, 2023 927 $ 9 $ \u2014 $ 89,994 $ ( 2,643 ) $ ( 5,007 ) $ 5,015 $ 87,368 Ba\n) $ 13,182 15 Table of Contents ITEM\u00a02.",
      "score": 0.9988
    },
    {
      "sent": "The following table summarizes the impact of hypothetical changes in market interest rates across the entire yield curve by 1% point or 2% points as of June\u00a030, 2023 on our investment income and interest expense per annum, and the fair value of our investments and debt (in millions, except percentages): June 30, 2023 Increase (Decrease) in Market Interest Rate Investment Income\u00a0Per Annum Interest Expense\u00a0Per Annum Fair\u00a0Value\u00a0of Financial Assets Fair\u00a0Value\u00a0of Financial Liabilities 2 % $ 1,025 $ 469 $ (3,500) $ (8,164) 1 512 234 (1,799) (4,458) (1) (512) (207) 1,882 5,415 (2) (1,025) (410) 3,817 12,059 Note: The impact of hypothetical changes in interest rates may not reflect the full 100 or 200 basis point change on interest income and interest expense or on the fair value of financial assets and liabilities as the rates are assumed to not fall below zero.",
      "score": 0.9876
    },
    {
      "sent": "The following table summarizes the impact of hypothetical changes in market interest rates across the entire yield curve by 1% point or 2% points as of June\u00a030, 2023 on our investment income and interest expense per annum, and the fair value of our investments and debt (in millions, except percentages): June 30, 2023 Increase (Decrease) in Market Interest Rate Investment Income\u00a0Per Annum Interest Expense\u00a0Per Annum Fair\u00a0Value\u00a0of Financial Assets Fair\u00a0Value\u00a0of Financial Liabilities 2 % $ 1,025 $ 469 $ (3,500) $ (8,164) 1 512 234 (1,799) (4,458) (1) (512) (207) 1,882 5,415 (2) (1,025) (410) 3,817 12,059 Note: The impact of hypothetical changes in interest rates may not reflect the full 100 or 200 basis point change on interest income and interest expense or on the fair value of financial assets and liabilities as the rates are assumed to not fall below zero.",
      "score": 0.9876
    }
  ],
  "top_negative": [
    {
      "sent": "By their nature, forward-looking statements are not guarantees of future performance or results and are subject to risks, uncertainties and assumptions that are difficult to predict or quantify.",
      "score": -0.7184
    },
    {
      "sent": "By their nature, forward-looking statements are not guarantees of future performance or results and are subject to risks, uncertainties and assumptions that are difficult to predict or quantify.",
      "score": -0.7184
    },
    {
      "sent": "By their nature, forward-looking statements are not guarantees of future performance or results and are subject to risks, uncertainties and assumptions that are difficult to predict or quantify.",
      "score": -0.7184
    }
  ],
  "forward_snippets": [
    "Readers are cautioned that the statements, estimates, projections or outlook contained in this Management's Discussion and Analysis of Financial Condition and Results of Operations, including discussions regarding financial prospects, economic conditions, trends and uncertainties contained in this Item\u00a02, may constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 (PSLRA).",
    "We expect overall spending on health care to continue to grow in the future due to inflation, medical technology and pharmaceutical advancement, regulatory requirements, demographic trends in the population and national interest in health and well-being.",
    "We will continue seeking to balance growth and profitability across all these dimensions.",
    "We expect broad-based competition to continue as the industry adapts to individual and employer needs.",
    "Additionally, we decide annually on a county-by-county basis where we will offer Medicare Advantage plans."
  ],
  "curated_text": "Symbol: UNH. Year: 2023. Period: Q2. ReportType: Q10. Section: Management Discussion and Analysis (MD&A). Key metrics include sentiment, forward outlook, and risk hedging.  Top positive sentences: FINANCIAL STATEMENTS UnitedHealth Group Condensed Consolidated Balance Sheets (Unaudited) (in millions, except per share data) June 30, 2023 December 31, 2022 Assets Current assets: Cash and cash equivalents $ 41,813 $ 23,365 Short-term investments 4,466 4,546 Accounts receivable, net 17,952 17,681 Other current receivables, net 16,131 12,769 Assets under management 3,623 4,087 Prepaid expenses and other current assets 5,884 6,621 Total current assets 89,869 69,069 Long-term investments 45,988 43,728 Property, equipment and capitalized software, net 10,926 10,128 Goodwill 101,669 93,352 Other intangible assets, net 15,643 14,401 Other assets 16,069 15,027 Total assets $ 280,164 $ 245,705 Liabilities, redeemable noncontrolling interests and equity Current liabilities: Medical costs payable $ 31,947 $ 29,056 Accounts payable and accrued liabilities 29,516 27,715 Short-term borrowings and current maturities of long-term debt 6,321 3,110 Unearned revenues 14,852 3,075 Other current liabilities 30,345 26,281 Total current liabilities 112,981 89,237 Long-term debt, less current maturities 59,268 54,513 Deferred income taxes 2,498 2,769 Other liabilities 13,261 12,839 Total liabilities 188,008 159,358 Commitments and contingencies (Note 7) Redeemable noncontrolling interests 4,788 4,897 Equity: Preferred stock, $ 0.001 par value - 10 shares authorized; no shares issued or outstanding \u2014 \u2014 Common stock, $ 0.01 par value - 3,000 shares authorized; 927 and 934 issued and outstanding 9 9 Retained earnings 89,994 86,156 Accumulated other comprehensive loss ( 7,650 ) ( 8,393 ) Nonredeemable noncontrolling interests 5,015 3,678 Total equity 87,368 81,450 Total liabilities, redeemable noncontrolling interests and equity $ 280,164 $ 245,705 See Notes to the Condensed Consolidated Financial Statements 1 Table of Contents UnitedHealth Group Condensed Consolidated Statements of Operations (Unaudited) Three Months Ended June 30, Six Months Ended June 30, (in millions, except per share data) 2023 2022 2023 2022 Revenues: Premiums $ 72,474 $ 63,896 $ 145,260 $ 127,966 Products 10,651 9,496 20,918 18,836 Services 8,663 6,645 16,743 13,017 Investment and other income 1,115 295 1,913 662 Total revenues 92,903 80,332 184,834 160,481 Operating costs: Medical costs 60,268 52,093 120,113 104,616 Operating costs 13,809 11,709 27,434 23,110 Cost of products sold 9,748 8,596 19,153 17,083 Depreciation and amortization 1,021 802 1,991 1,590 Total operating costs 84,846 73,200 168,691 146,399 Earnings from operations 8,057 7,132 16,143 14,082 Interest expense ( 828 ) ( 467 ) ( 1,582 ) ( 900 ) Earnings before income taxes 7,229 6,665 14,561 13,182 Provision for income taxes ( 1,572 ) ( 1,466 ) ( 3,130 ) ( 2,835 ) Net earnings 5,657 5,199 11,431 10,347 Earnings attributable to noncontrolling interests ( 183 ) ( 129 ) ( 346 ) ( 250 ) Net earnings attributable to UnitedHealth Group common shareholders $ 5,474 $ 5,070 11,085 $ 10,097 Earnings per share attributable to UnitedHealth Group common shareholders: Basic $ 5.89 $ 5.41 $ 11.91 $ 10.75 Diluted $ 5.82 $ 5.34 $ 11.77 $ 10.61 Basic weighted-average number of common shares outstanding 930 937 931 939 Dilutive effect of common share equivalents 10 13 11 13 Diluted weighted-average number of common shares outstanding 940 950 942 952 Anti-dilutive shares excluded from the calculation of dilutive effect of common share equivalents 7 3 6 3 See Notes to the Condensed Consolidated Financial Statements 2 Table of Contents UnitedHealth Group Condensed Consolidated Statements of Comprehensive Income (Unaudited) Three Months Ended June 30, Six Months Ended June 30, (in millions) 2023 2022 2023 2022 Net earnings $ 5,657 $ 5,199 $ 11,431 $ 10,347 Other comprehensive (loss) income: Gross unrealized (losses) gains on investment securities during the period ( 431 ) ( 1,331 ) 209 ( 3,354 ) Income tax effect 99 304 ( 48 ) 769 Total unrealized (losses) gains, net of tax ( 332 ) ( 1,027 ) 161 ( 2,585 ) Gross reclassification adjustment for net realized gains included in net earnings ( 47 ) ( 1 ) ( 34 ) ( 4 ) Income tax effect 11 \u2014 8 1 Total reclassification adjustment, net of tax ( 36 ) ( 1 ) ( 26 ) ( 3 ) Total foreign currency translation gains (losses) 267 ( 676 ) 608 242 Other comprehensive (loss) income ( 101 ) ( 1,704 ) 743 ( 2,346 ) Comprehensive income 5,556 3,495 12,174 8,001 Comprehensive income attributable to noncontrolling interests ( 183 ) ( 129 ) ( 346 ) ( 250 ) Comprehensive income attributable to UnitedHealth Group common shareholders $ 5,373 $ 3,366 $ 11,828 $ 7,751 See Notes to the Condensed Consolidated Financial Statements 3 Table of Contents UnitedHealth Group Condensed Consolidated Statements of Changes in Equity (Unaudited) Common Stock Additional Paid-In Capital Retained Earnings Accumulated Other Comprehensive (Loss) Income Nonredeemable Noncontrolling Interests Total Equity Three months ended June 30, (in millions) Shares Amount Net Unrealized (Losses) Gains on Investments Foreign Currency Translation (Losses) Gains Balance at March 31, 2023 932 $ 9 $ \u2014 $ 88,852 $ ( 2,275 ) $ ( 5,274 ) $ 4,509 $ 85,821 Net earnings 5,474 139 5,613 Other comprehensive (loss) income ( 368 ) 267 ( 101 ) Issuances of common stock, and related tax effects 1 \u2014 218 218 Share-based compensation 232 232 Common share repurchases ( 6 ) \u2014 ( 442 ) ( 2,585 ) ( 3,027 ) Cash dividends paid on common shares ($ 1.88 per share) ( 1,747 ) ( 1,747 ) Redeemable noncontrolling interests fair value and other adjustments ( 8 ) ( 8 ) Acquisition and other adjustments of nonredeemable noncontrolling interests 478 478 Distribution to nonredeemable noncontrolling interests ( 111 ) ( 111 ) Balance at June 30, 2023 927 $ 9 $ \u2014 $ 89,994 $ ( 2,643 ) $ ( 5,007 ) $ 5,015 $ 87,368 Balance at March 31, 2022 939 $ 10 $ \u2014 $ 78,782 $ ( 1,137 ) $ ( 4,889 ) $ 3,362 $ 76,128 Net earnings 5,070 94 5,164 Other comprehensive loss ( 1,028 ) ( 676 ) ( 1,704 ) Issuances of common stock, and related tax effects 1 \u2014 174 174 Share-based compensation 194 194 Common share repurchases ( 5 ) \u2014 ( 733 ) ( 1,767 ) ( 2,500 ) Cash dividends paid on common shares ($ 1.65 per share) ( 1,545 ) ( 1,545 ) Redeemable noncontrolling interests fair value and other adjustments 365 365 Acquisition and other adjustments of nonredeemable noncontrolling interests 12 12 Distribution to nonredeemable noncontrolling interests ( 83 ) ( 83 ) Balance at June 30, 2022 935 $ 10 $ \u2014 $ 80,540 $ ( 2,165 ) $ ( 5,565 ) $ 3,385 $ 76,205 See Notes to the Condensed Consolidated Financial Statements 4 Table of Contents UnitedHealth Group Condensed Consolidated Statements of Changes in Equity (Unaudited) Common Stock Additional Paid-In Capital Retained Earnings Accumulated Other Comprehensive (Loss) Income Nonredeemable Noncontrolling Interests Total Equity Six months ended March 31, (in millions) Shares Amount Net Unrealized (Losses) Gains on Investments Foreign Currency Translation (Losses) Gains Balance at January 1, 2023 934 $ 9 $ \u2014 $ 86,156 $ ( 2,778 ) $ ( 5,615 ) $ 3,678 $ 81,450 Net earnings 11,085 252 11,337 Other comprehensive income 135 608 743 Issuances of common stock, and related tax effects 3 \u2014 568 568 Share-based compensation 598 598 Common share repurchases ( 10 ) \u2014 ( 1,075 ) ( 3,963 ) ( 5,038 ) Cash dividends paid on common shares ($ 3.53 per share) ( 3,284 ) ( 3,284 ) Redeemable noncontrolling interests fair value and other adjustments ( 91 ) ( 91 ) Acquisition and other adjustments of nonredeemable noncontrolling interests 1,297 1,297 Distribution to nonredeemable noncontrolling interests ( 212 ) ( 212 ) Balance at June 30, 2023 927 $ 9 $ \u2014 $ 89,994 $ ( 2,643 ) $ ( 5,007 ) $ 5,015 $ 87,368 Ba\n) $ 13,182 15 Table of Contents ITEM\u00a02. The following table summarizes the impact of hypothetical changes in market interest rates across the entire yield curve by 1% point or 2% points as of June\u00a030, 2023 on our investment income and interest expense per annum, and the fair value of our investments and debt (in millions, except percentages): June 30, 2023 Increase (Decrease) in Market Interest Rate Investment Income\u00a0Per Annum Interest Expense\u00a0Per Annum Fair\u00a0Value\u00a0of Financial Assets Fair\u00a0Value\u00a0of Financial Liabilities 2 % $ 1,025 $ 469 $ (3,500) $ (8,164) 1 512 234 (1,799) (4,458) (1) (512) (207) 1,882 5,415 (2) (1,025) (410) 3,817 12,059 Note: The impact of hypothetical changes in interest rates may not reflect the full 100 or 200 basis point change on interest income and interest expense or on the fair value of financial assets and liabilities as the rates are assumed to not fall below zero. The following table summarizes the impact of hypothetical changes in market interest rates across the entire yield curve by 1% point or 2% points as of June\u00a030, 2023 on our investment income and interest expense per annum, and the fair value of our investments and debt (in millions, except percentages): June 30, 2023 Increase (Decrease) in Market Interest Rate Investment Income\u00a0Per Annum Interest Expense\u00a0Per Annum Fair\u00a0Value\u00a0of Financial Assets Fair\u00a0Value\u00a0of Financial Liabilities 2 % $ 1,025 $ 469 $ (3,500) $ (8,164) 1 512 234 (1,799) (4,458) (1) (512) (207) 1,882 5,415 (2) (1,025) (410) 3,817 12,059 Note: The impact of hypothetical changes in interest rates may not reflect the full 100 or 200 basis point change on interest income and interest expense or on the fair value of financial assets and liabilities as the rates are assumed to not fall below zero. Top negative sentences: By their nature, forward-looking statements are not guarantees of future performance or results and are subject to risks, uncertainties and assumptions that are difficult to predict or quantify. By their nature, forward-looking statements are not guarantees of future performance or results and are subject to risks, uncertainties and assumptions that are difficult to predict or quantify. By their nature, forward-looking statements are not guarantees of future performance or results and are subject to risks, uncertainties and assumptions that are difficult to predict or quantify. Forward-looking snippets: Readers are cautioned that the statements, estimates, projections or outlook contained in this Management's Discussion and Analysis of Financial Condition and Results of Operations, including discussions regarding financial prospects, economic conditions, trends and uncertainties contained in this Item\u00a02, may constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 (PSLRA). We expect overall spending on health care to continue to grow in the future due to inflation, medical technology and pharmaceutical advancement, regulatory requirements, demographic trends in the population and national interest in health and well-being. We will continue seeking to balance growth and profitability across all these dimensions. We expect broad-based competition to continue as the industry adapts to individual and employer needs. Additionally, we decide annually on a county-by-county basis where we will offer Medicare Advantage plans."
}